Unlocking the Dual Role of LSD1 in Tumor Immunity: Innate and Adaptive Pathways

Overview

Journal Theranostics

Date 2024 Dec 4

PMID 39629133

Authors

Yu Zhang

Ningjie Guo

Haoyi Zhu

Mengyang Liu

Jiahui Hao

Shoukai Wang

Ting Guo

Maa Mamun

Jingru Pang

Qi Liu

Yichao Zheng

Hongmin Liu

Pilei Si

Lijuan Zhao

Affiliations

Soon will be listed here.

Abstract

The roles of innate and adaptive immunity are crucial in both the development of cancer and its response to treatment. Numerous studies have demonstrated that histone lysine-specific demethylase 1 (LSD1) is overexpressed in various cancers. Elevated levels of LSD1 intricately modulate immune checkpoints, the function of immune cells, and the expression of immunomodulators, impacting both innate and adaptive immunity. Moreover, compelling evidence suggests that inhibiting LSD1 enhances tumor immunity, suppresses tumor growth, and improves the effectiveness of immunotherapy. However, a comprehensive classification of LSD1's role in both innate and adaptive immunity is lacking. In this review, we outline the role of LSD1 in tumor immunity in terms of both innate and adaptive immunity, summarizing the mechanisms associated with LSD1-mediated tumor immunity and its potential regulatory capacity in tumor immune escape. Finally, we summarize the research status of LSD1 inhibitors in tumor immunotherapy, which be valuable for promoting the development of effective LSD1-targeted agents used as combination immunotherapy drugs.

References

Lan F, Nottke A, Shi Y . Mechanisms involved in the regulation of histone lysine demethylases. Curr Opin Cell Biol. 2008; 20(3):316-25. PMC: 2674377. DOI: 10.1016/j.ceb.2008.03.004. View

Gu T, Vasilatos S, Yin J, Qin Y, Zhang L, Davidson N . Restoration of TFPI2 by LSD1 inhibition suppresses tumor progression and potentiates antitumor immunity in breast cancer. Cancer Lett. 2024; 600:217182. PMC: 11384719. DOI: 10.1016/j.canlet.2024.217182. View

Sheng W, LaFleur M, Nguyen T, Chen S, Chakravarthy A, Conway J . LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018; 174(3):549-563.e19. PMC: 6063761. DOI: 10.1016/j.cell.2018.05.052. View

Guo S, Deng C . Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation. Int J Biol Sci. 2018; 14(14):2083-2093. PMC: 6299363. DOI: 10.7150/ijbs.25720. View

Peng J, Wang L, Li Z, Ku C, Ho P . Metabolic challenges and interventions in CAR T cell therapy. Sci Immunol. 2023; 8(82):eabq3016. DOI: 10.1126/sciimmunol.abq3016. View

He Q, Jiang X, Zhou X, Weng J . Targeting cancers through TCR-peptide/MHC interactions. J Hematol Oncol. 2019; 12(1):139. PMC: 6921533. DOI: 10.1186/s13045-019-0812-8. View

Laumont C, Nelson B . B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell. 2023; 41(3):466-489. DOI: 10.1016/j.ccell.2023.02.017. View

Apte R, Chen D, Ferrara N . VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019; 176(6):1248-1264. PMC: 6410740. DOI: 10.1016/j.cell.2019.01.021. View

Han Y, Xu S, Ye W, Wang Y, Zhang X, Deng J . Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade. Cell Death Dis. 2021; 12(11):993. PMC: 8542042. DOI: 10.1038/s41419-021-04297-0. View

10.

Yu L, Xiao Q, Yu B, Lv Q, Liu Z, Yin J . CircRNAs in tumor immunity and immunotherapy: Perspectives from innate and adaptive immunity. Cancer Lett. 2023; 564:216219. DOI: 10.1016/j.canlet.2023.216219. View

11.

Baggiolini M, DEWALD B, Moser B . Human chemokines: an update. Annu Rev Immunol. 1997; 15:675-705. DOI: 10.1146/annurev.immunol.15.1.675. View

12.

Suzuki J, Maruyama S, Tamauchi H, Kuwahara M, Horiuchi M, Mizuki M . Gfi1, a transcriptional repressor, inhibits the induction of the T helper type 1 programme in activated CD4 T cells. Immunology. 2016; 147(4):476-87. PMC: 4799889. DOI: 10.1111/imm.12580. View

13.

Hao Y, Baker D, Ten Dijke P . TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci. 2019; 20(11). PMC: 6600375. DOI: 10.3390/ijms20112767. View

14.

Dong B, Wang X, Song X, Wang J, Liu X, Yu Z . RNF20 contributes to epigenetic immunosuppression through CDK9-dependent LSD1 stabilization. Proc Natl Acad Sci U S A. 2024; 121(7):e2307150121. PMC: 10873621. DOI: 10.1073/pnas.2307150121. View

15.

Srivastava P, Tzetzo S, Gomez E, Eng K, Jani Sait S, Kuechle J . Inhibition of LSD1 in MDS progenitors restores differentiation of CD141 conventional dendritic cells. Leukemia. 2020; 34(9):2460-2472. PMC: 7483249. DOI: 10.1038/s41375-020-0765-5. View

16.

Leonard W, Lin J . Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov. 2023; 22(10):827-854. DOI: 10.1038/s41573-023-00746-x. View

17.

Liu C, Liu L, Chen X, Cheng J, Zhang H, Zhang C . LSD1 Stimulates Cancer-Associated Fibroblasts to Drive Notch3-Dependent Self-Renewal of Liver Cancer Stem-like Cells. Cancer Res. 2017; 78(4):938-949. DOI: 10.1158/0008-5472.CAN-17-1236. View

18.

Sacca C, Gorini F, Ambrosio S, Amente S, Faicchia D, Matarese G . Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF-1α-dependent pathway. Biochim Biophys Acta Gene Regul Mech. 2019; 1862(5):535-546. DOI: 10.1016/j.bbagrm.2019.03.004. View

19.

Alhousami T, Diny M, Ali F, Shin J, Kumar G, Kumar V . Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition. Mol Cancer Res. 2022; 20(5):712-721. PMC: 9081163. DOI: 10.1158/1541-7786.MCR-21-0310. View

20.

Wang B, Zhou Y, Zhang J, Jin X, Wu H, Huang H . Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. Theranostics. 2020; 10(3):1033-1045. PMC: 6956820. DOI: 10.7150/thno.38137. View